Granted Patent
B2
US 12,570,983 · App. 18/821,573 · Granted Mar 10, 2026
Composition for regulating production of interfering ribonucleic acid
Assignee:
Wyvern Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule, such as CXCR4. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to expression of the target biomolecule.
Claims (2)
1 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO: 2.
2 . The composition of claim 1 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 30, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072417/0636 →
Continuity (1)
References Cited (41)
CA 2721333A1
· 2009
[cited by applicant]
Hughes and Nibbs, 2018, “A guide to chemokines and their receptors” The FEBS Journal, 285, p. 2944-2971 (Year: 2018).
[cited by examiner]
O'Brien, et al., Aug. 3, 2018, “Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation” Front Endocrinol (Lausanne), 9:402, p. 1-12 (Year: 2018).
[cited by examiner]
Lu et al., Oct. 29, 2013, “miR-9 targets CXCR4 and functions as a potential tumor suppressor in nasopharyngeal carcinoma” Carcinogenesis, p. 554-563 (Year: 2013).
[cited by examiner]
Ren et al., 2020, “MiR-140-3p Ameliorates the Progression of Osteoarthritis via Targeting CXCR4” Biol. Pharm. Bull., 43, p. 810-816 (Year: 2020).
[cited by examiner]
Agarwal et al., 2015, “Predicting effective microRNA target sites in mammalian mRNAs” eLife, 4: e05005 (Year: 2015).
[cited by examiner]
[cited by examiner]
[cited by examiner]
[cited by examiner]
[cited by examiner]
[cited by examiner]
[cited by examiner]
Momin et al., 2021, Cells, 10, 3097, p. 1-21 (Year: 2021).
[cited by examiner]
Bottoni et al. “Targeting BTK through microRNA in chronic lymphocytic leukemia.” Blood, The Journal of the American Society of Hematology 128.26 (2016): 3101-3112.
[cited by applicant]
Brutons Tyrosine Kinase Genbank Sequence (2023).
[cited by applicant]
Christensen et al. “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848.
[cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166.
[cited by applicant]
Van den Berg, et al., pp. 1-12, Molecular Therapy—Nucleic Acids, vol. 5, 2016 (Year: 2016).
[cited by applicant]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (2010).
[cited by applicant]
GenBank EGF Sequence (2023).
[cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253.
[cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494.
[cited by applicant]
Clark et al. “Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.” Oncotarget 11.44 (2020): 4016.
[cited by applicant]
NCBI search results for SEQ ID No. 5 (2024).
[cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023).
[cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023).
[cited by applicant]
GenBank EGFR Sequence (2023).
[cited by applicant]
Genbank FLT3 Sequence (2024).
[cited by applicant]
NCBI Nucleotide Sequence for PARP, search performed Dec. 26, 2024 (2024).
[cited by applicant]
Tritschler et al. “Concepts and limitations for learning developmental trajectories from single cell genomics.” Development 146.12 (2019): dev170506.
[cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675.
[cited by applicant]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery”. Nat Rev Drug Discov. May 2019;18(5):358-378. (Year: 2019).
[cited by applicant]
Gorski, S., Vogel, J. & Doudna, J. RNA-based recognition and targeting: sowing the seeds of specificity. Nat Rev Mol Cell Biol 18, 215-228 (2017). (Year: 2017).
[cited by applicant]
Denzler R et al. Impact of MicroRNA Levels, Target-Site Complementarity, and Cooperativity on Competing Endogenous RNA-Regulated Gene Expression. Mol Cell. Nov. 3, 2016;64(3):565-579. doi: 10.1016/j.molcel.2016.09.027 (…
[cited by applicant]